Durée :2018-2021

Participants :Consortium : Jean-Pierre Benoit (Coordinator)
INSERM U1066/CNRS UMR 6021, University of Angers
4 Rue Larrey
49933, Angers, France

Giovanna Lollo
LAGEP - UMR CNRS 5007 University Claude Bernard Lyon 1
8 avenue Rockefeller
69373, Lyon, France

Vincenzo Bronte
Department of Medicine, University of Verona
P.le L. A. Scuro, 10
37134, Verona, Italy

Pål Sætrom
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology – NTNU
Erling Skjalgssons gt. 1
NO-7491, Trondheim, Norway

Ugur Sahin
BioNTech RNA Pharmaceuticals
An der Goldgrube 12
55131, Mainz, Rhineland-Palatinate, Germany

RESOLVE : SuppRESsion of immunopathology by nanOparticle deLiVEry of mRNA to monocytes

The aim of RESOLVE is to pursue the development of innovative nanosystems as novel therapeutic approaches based on the engineering of nanomedicine to limit the immune reactivity against host self-antigens in the course of bone marrow transplantation (graft versus host disease, GvHD) and autoimmune diseases (multiple sclerosis, MS). Currently, therapeutics for these pathologies are based on either systemic or local immunosuppression, which eliminate or suppress polyclonal, autoreactive T-cell specificities while compromising the entire systemic immunity with many side effects, sometimes life threatening. But the most promising strategies to come are represented by either restoration or de novo induction of cells able to induce tolerance, such as the monocytic myeloid-derived suppressor cells (MO-MDSCs). Their immunosuppressive activity, and consequently their tolerogenic ability, can be enhanced by increasing the cellular level of a protein involved in apoptosis regulation, CFLAR. In the course of the present project, new nanosystems will be designed to specifically target in vivo the MO-MDSCs, and efficiently deliver mRNAs to produce CFLAR. The specific expression of the protein, both at the cellular and tissue levels, the in vivo nanosystem biodistribution and the therapeutic efficacy in mouse models of GvHD and MS, will be assessed.


Find the video ” Discover how mRNA nanoparticles have been engineered for the treatment of autoimmune diseases” presenting the RESOLVE project below or in YouTube :

Filed under: Uncategorised